Surveillance Test

High sensitivity pooled antigen testing

The LumiraDx SARS-CoV-2 Ag Surveillance Test is a rapid microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal specimens allowing a pooled testing approach of up to 5 specimens.

Stay vigilant, Keep rates low and confidence high

  • Lab-comparable results in 12-minutes, The LumiraDx SARS-CoV-2 Ag Surveillance Test delivers fast, accurate, cost-efficient pooled surveillance testing onsite.
  • Up to 5 specimens may be pooled and added to a single test strip, without sacrificing sensitivity
  • 100.0% positive agreement and 96.6% negative agreement with the LumiraDx SARS-CoV-2 Ag Test

Test Workflow

Simple sample prep along with step-by-step on-screen guidance. Results available in 12 minutes.

Rapid, cost-efficient, scalable with cloud based connectivity

Verify that COVID-19 isn’t spreading in your population, quickly implement preventative measures when clusters emerge.

  • Faster results deliver peace of mind
  • Respond quickly to escalate contact precautions, limiting spread thereby maintaining productivity

The LumiraDx SARS-CoV-2 Ag Surveillance Test has not been cleared, approved, or authorized by FDA. This test should be used for surveillance purposes (i.e., to inform population or community-level decision-making on de-identified specimens) only. FDA does not regulate surveillance tests.